Kinase inhibitor conjugates.

S, Harmsen, R.J. Kok

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In the last decade kinase inhibitors have emerged as a new class of very potent and relatively safe anticancer drugs. However, despite their success, off-target toxicities and induction of rapid resistance are major drawbacks that highly compromise successful longterm administration. In the current review, we provide an overview of the approaches that have been undertaken to overcome these issues by conjugation of these agents to carriers that enable their cellular and/or intracellular targeted delivery. Eventually, targeting kinase inhibitors will provide powerful treatment options not only for cancer, but also for other less-life threatening diseases that involve deregulated kinase signaling pathways.
Original languageUndefined/Unknown
Pages (from-to)2891-900
Number of pages10
JournalCurrent Pharmaceutical Design
Volume18
Issue number20
Publication statusPublished - 2012

Cite this